ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
GSK plc ADRhedged
69.80
+2.83
4.23%
盤後:
69.80
0.0000
0.00%
16:10 EDT
成交量:
858
成交額:
5.98萬
市值:
69.81萬
市盈率:
- -
高:
70.05
開:
69.80
低:
69.34
收:
66.97
52周最高:
85.03
52周最低:
55.75
股本:
1.00萬
流通股本:
1.00萬
量比:
4.75
換手率:
8.58%
股息:
2.08
股息率:
2.97%
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
118款生物藥專利懸崖將至,中國藥企業迎戰MNC最大專利懸崖
蓝鲸财经
·
09/10
乙肝新藥中國數據出爐,但實現患者的「治癒夢」仍有門檻
每日经济新闻
·
09/08
功能性治癒率最高61%!乙肝新藥中國數據出爐 但7500萬患者的「治癒夢」仍有門檻
每日经济新闻
·
09/05
總額可達12.95億美元!和黃全球首創偶聯藥物出海
时代周报
·
09/03
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/GSKH"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":69.8025,"timestamp":1789416000000,"preClose":66.9705,"halted":0,"volume":858,"hourTrading":{"tag":"盘后","latestPrice":69.8025,"preClose":69.8025,"latestTime":"16:10 EDT","volume":6,"amount":418.81499999999994,"timestamp":1789416603787,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.042287275740811155,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"盤後交易","change":2.832,"latestTime":"09-14 16:56:42 EDT","open":69.8,"high":70.05,"low":69.34,"amount":59772,"amplitude":0.010602,"askPrice":104.71,"askSize":200,"bidPrice":34.91,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789430400000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":66.9705,"nav":66.980718,"aum":669874.160718,"dividendRate":0.029742,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":69.8025,"preClose":69.8025,"latestTime":"16:10 EDT","volume":6,"amount":418.81499999999994,"timestamp":1789416603787,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":4.745573,"impliedVol":0.1896,"impliedVolPercentile":0.4649},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":4.745573,"shares":10001,"dividePrice":2.0761,"high":70.05,"amplitude":0.010602,"preClose":66.9705,"low":69.34,"week52Low":55.7526,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":69.8025,"eps":0,"divideRate":0.029742,"volume":858,"delay":0,"ttmEps":0,"open":69.8,"prevYearClose":68.2031,"prevWeekClose":66.9705,"prevMonthClose":69.8569,"prevQuarterClose":73.8574,"fiveDayClose":69.5112,"twentyDayClose":68.9018,"sixtyDayClose":73.2027},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"GSKH","amount":0.92785,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.92785,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666563124","title":"118款生物藥專利懸崖將至,中國藥企業迎戰MNC最大專利懸崖","url":"https://stock-news.laohu8.com/highlight/detail?id=2666563124","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666563124?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 15:26","pubTimestamp":1789025185,"startTime":"0","endTime":"0","summary":"BCG合伙人杜菁博士指出,未来几年全球MNC将迎来史上最大专利悬崖,有118种生物制剂将会失去相应的专利保护,涉及2340亿美元市场。然而,目前这118款即将到期分子中,只有极少数在火热开发,大量缺口有待生物类似药填补。目前来说,创新药出海还没办法完成这个闭环,但生物类似药作为先头部队做出海试验,企业风险和获益会更高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789025064363150858","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["RSPH","159839","PJP","BBP","APXH","BME","MEDI","TMED","PBPH","GSKH","IHE","BBH","IYH","PPH","TRUH","FXH","JDOC","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665937331","title":"乙肝新藥中國數據出爐,但實現患者的「治癒夢」仍有門檻","url":"https://stock-news.laohu8.com/highlight/detail?id=2665937331","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665937331?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:51","pubTimestamp":1788871868,"startTime":"0","endTime":"0","summary":"中国慢性乙型肝炎(以下简称慢乙肝)患者的“治愈”故事,正在萌芽。日前,在新加坡召开的亚洲肝病学峰会暨乙肝病毒治愈科学会议上,反义寡核苷酸(ASO)药物Bepirovirsen全球Ⅲ期研究(BWell研究)的中国人群数据完成了全球首秀:中国慢乙肝患者功能性治愈率最高可达61%,疗效与安全性趋势与全球数据一致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868286383.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868286383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","BK4585","LU1829250122.USD","BK4532","GSK","GSKH","GSK.UK","BK4561","ASO","BK4588","BK4200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665535012","title":"功能性治癒率最高61%!乙肝新藥中國數據出爐 但7500萬患者的「治癒夢」仍有門檻","url":"https://stock-news.laohu8.com/highlight/detail?id=2665535012","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665535012?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 12:14","pubTimestamp":1788581677,"startTime":"0","endTime":"0","summary":"【功能性治愈率最高61%!乙肝新药中国数据出炉 但7500万患者的“治愈梦”仍有门槛】8月31日—9月5日,在新加坡召开的亚洲肝病学峰会(AHS)暨HBV(乙型肝炎病毒)治愈科学会议上,反义寡核苷酸(ASO)药物Bepirovirsen全球Ⅲ期研究(B-Well研究)的中国人群数据完成了全球首秀:中国慢乙肝患者功能性治愈率最高可达61%,疗效与安全性趋势与全球数据一致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609053865995314.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609053865995314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["XME","CHB","LU1829250122.USD","BK4007","BK4561","BK4599","CDE","ASO","BK4532","BK4139","BK4585","SIL","LU1223083913.SGD","GSK.UK","ALT","LU1223082196.USD","SGDM","GSKH","BK4588","LU1223082519.USD","LU1878469433.USD","GDXJ","GSK","BK4200","BK4017"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664960827","title":"總額可達12.95億美元!和黃全球首創偶聯藥物出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2664960827","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664960827?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:03","pubTimestamp":1788422625,"startTime":"0","endTime":"0","summary":"9月3日,和黄医药(00013.HK)宣布旗下子公司和记黄埔与葛兰素史克(GSK)附属公司达成独家开发及许可协议,授予后者除中国大陆、香港、澳门和台湾以外的全球范围内开发和商业化HMPL-A830的权利。临床开发将首先聚焦于结直肠癌、胰腺癌和肺癌适应症。协议包括1.1亿美元的首付款以及潜在的开发、注册和商业化里程碑付款,总额可达12.95亿美元,外加基于净销售额的特许权使用费。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864044420.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033864044420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK4532","GSK.UK","GSKH","LU1829250122.USD","BK1588","BK4007","BK4585","BK4588","BK1587","00013","GSK"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":24,"pageCount":1,"totalSize":96,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/GSKH\",params:#limit:6,delay:false,,,undefined,":[]}}